AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Introductory guidance on choosing long-term holds for beginners, focusing on fundamentals, liquidity, and project viability.
27,784 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
The IMF slashed its 2026 global growth forecast to 3.0% amid the Iran conflict, but AI-driven investment and technolo...
SpaceX faces a towering IPO target: a $1.5 trillion market cap. Analysts say the math hinges on unprecedented growth ...
Global markets tumbled as President Trump signaled a major escalation with Iran, sending oil higher and volatility so...
NVIDIA breached a $5.5 trillion market cap, marking a historic leap for a chipmaker tied to AI. The move highlights t...
Health care cost growth continues to outpace Social Security COLAs, sparking protests from retirees and prompting con...
June 11 brought a surprising twist: Coupang’s privacy fine landed below feared levels, sending the stock higher and l...
Adobe Stock sits at a crossroads as the company leans into AI, subscriptions, and enterprise workflows. This guide ex...
Netflix signals a major strategic shift toward live television and third-party distributions to boost engagement as a...
Three under-the-radar service firms are posting double-digit revenue gains and resilient margins, signaling opportuni...
Wall Street leaned on a familiar Fed playbook for years. Now a surprising pivot in that script could rattle stocks an...
When lawmakers push for accountability during a shutdown, families worry about cash flow. This guide breaks down what...